NCT06181006View on ClinicalTrials.gov

A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions

Healthy

Interventions

DRUG

Pirtobrutinib

Administered orally.

Trial Locations (1)

32117

Covance Clinical Research Unit, Daytona Beach

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06181006 - A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants | Biotech Hunter | Biotech Hunter